The role of tryptophan and its metabolites, including 3-hydroxykunurenine (3-HK), quinolinic acid (QA), kynurenic acid (KA), and others are receiving attention due to their immunomodulatory and neuromodulatory effects. We offer a range of enzymes in this pathway, including Tryptophan Dioxygenases (TDO), Kynurenine 3-Monooxygenase (KMO), Indoleamine 2,3-dioxygenases (IDO), Kynurenine Aminotransferases (KAT), and Kynureninase (KYNU).
Dysfunction or modulation of the pathway has been linked to a range of nervous systems disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Schizophrenia, and others. IDO and TDO catalyze the first step in the pathway and act as immune suppressors of the tumor microenvironment. As a result, they are perhaps best known for their role as immunotherapeutic drug targets.
Browse our website for a complete listing of related enzymes, antibodies, small molecules.
New Recombinant Human IDO2. Recombinant Human IDO2 (Catalog # 9967-AO) is measured by its ability to oxidize L-tryptophan to N-formyl-kynurenine. The activity (orange) is approximately 4-fold greater than the competitor's IDO2 (green). Negative Control is shown in red.
New Recombinant Human TDO2 (Catalog
# 9768-TD) is measured by its ability to oxidize
L-tryptophan to N-formyl-kynurenine. The
activity (orange) is approximately 10-fold greater than the competitor's TDO2 (green).